AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...

AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ® ...

AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...

Studies evaluating the oral JAK inhibitor in adults and adolescents with non-segmental vitiligo are submitted for approval of the expanded indication.

For patients who had 12 months of continuous health care coverage before and after receiving a diagnosis of vitiligo, treatment rates were at suboptimal levels. Using data from the Merative MarketScan ...

A panel discussion that took place at the 2023 Fall Clinical Dermatology Conference focused on the importance of information to treat both vitiligo and atopic dermatitis. Atopic dermatitis (AD) and ...

CARLSBAD, Calif. — When patients with vitiligo see Jessica Shiu, MD, PhD, for the first time, some mention that prior healthcare providers have told them that vitiligo is merely a cosmetic issue — ...

Vitiligo is often misunderstood as merely a cosmetic issue, but for millions worldwide—including over a million in India—it’s a deeply personal and emotional struggle. Characterised by the loss of ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...